Q2 2025 Hims & Hers Health Inc Earnings Call Transcript
Key Points
- Hims & Hers Health Inc (HIMS) reported a 73% year-over-year revenue growth to $545 million in Q2 2025, with an adjusted EBITDA margin exceeding 15%.
- The company is expanding its platform with new specialties, including hormonal health, which is expected to address significant health issues for both men and women.
- Hims & Hers Health Inc (HIMS) successfully acquired ZAVA, enhancing its presence in the UK and establishing a foundation for further expansion in Europe and Canada.
- The company is investing in AI and technology to enhance personalized care, aiming to provide 24/7 support and improve patient engagement.
- Hims & Hers Health Inc (HIMS) plans to offer lab testing as a standalone service, which is expected to empower customers with better health insights and proactive health management.
- The company faced headwinds from off-boarding GLP-1 subscribers on commercially available dosages, impacting revenue recognition.
- There is a decline in the on-demand sexual health subscriber base, which is expected to continue affecting revenue in the short term.
- Hims & Hers Health Inc (HIMS) reported a negative free cash flow of $69 million in Q2 2025 due to significant investments in inventory and working capital.
- The transition towards more premium daily offerings in the sexual health segment is causing temporary revenue declines.
- The company anticipates increased marketing and technology investments, which may pressure margins in the near term.
Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to the Hims & Hers second-quarter 2025 earnings call. (Operator Instructions)
I would now like to turn the call over to Bill Newby, Head of Investor Relations. Bill, please go ahead.
Good afternoon, everyone, and welcome to the Hims & Hers Health second-quarter 2025 earnings call. Today, after the market closed, we released this quarter's shareholder letter, a copy of which you can find on our website at investors.hims.com.
On the call with me today is Andrew Dudum, our Co-Founder and Chief Executive Officer; Oluyemi Okupe, our Chief Financial Officer; and our new Chief Technology Officer, Mo Elshenawy.
Before I hand it over to Andrew, I need to remind you of legal Safe Harbor and cautionary declarations. Certain statements and projections of future results made in this presentation constitute forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
